



**Simposio Internacional: Enfermedades neuromusculares: es el tiempo para el tratamiento**

***International Symposium: Neuromuscular diseases: It's time for treatment***

Madrid, 15 y 16 de noviembre de 2012

*Madrid, November 15-16, 2012*

## **New antibodies related to neuromuscular diseases**

Isabel Illa Sendra

Neuromuscular diseases are an heterogeneous group of disease of different origin. They may be due to neurodegenerative, genetic, metabolic or other causes and some are immune-mediated. Chronic inflammatory demyelinating neuropathy (CIDP), multifocal motor neuropathy (MMN), inflammatory myopathies (IM) or Myasthenia Gravis (MG)) are among the neuromuscular diseases of probable autoimmune origin because they respond to plasmapheresis or immunosuppressive drugs and because antibodies to relevant antigens or inflammation have been found in a number of patients in these groups of pathologies.

I will review the importance of unraveling biomarkers for these diseases in order to better understand the clinical features, to further study their immunopathogenesis, and to apply more specific treatments. Specifically I will discuss the clinical findings , long-term immunological evolution and response to therapy of patients with MG-MuSK+ versus patients MG-AchR+. I will also present the clinical phenotype of patients with CIDP and antibodies to the CNTN-1- or the CNTN-1-CAPR-1 complex, proteins present at the paranodes of Ranvier.

\*Todos los derechos de propiedad intelectual son del autor. Queda prohibida la reproducción total o parcial de la obra sin autorización expresa del autor.

© FUNDACIÓN RAMÓN ARECES. Todos los derechos reservados.

*\*All intellectual property rights belong to the author. Total or partial reproduction of the work without express permission of the author is forbidden.*

*© FUNDACIÓN RAMÓN ARECES. All rights reserved.*